文献速递前列腺癌

快速PSA倍增时间(<9个月)的非转移性前列腺癌男性启动雄激素剥夺治疗时,去势抵抗性前列腺癌时间是否为转移时间的潜在中间终点

Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-09-01

本研究纳入根治性前列腺切除术后生化复发、PSA倍增时间<9个月且启动雄激素剥夺治疗时无转移的210例男性,评估无去势抵抗生存与无转移生存的相关性。中位无转移生存为104个月(95%CI:83-114),中位无去势抵抗生存为100个月(95%CI:80-114)。Kendall's Tau显示两者高度相关(0.867,95%CI:0.765-0.968),作者认为经验证后无去势抵抗生存可能作为潜在中间终点。

要点

  • 中位无转移生存104个月(95%CI:83-114),中位无去势抵抗生存100个月(95%CI:80-114)。
  • 无去势抵抗生存与无转移生存的Kendall's Tau为0.867(95%CI:0.765-0.968)。
  • 去势抵抗时间与转移时间的Kendall's Tau为0.764(95%CI:0.644-0.884)。

核心结论

  • 鉴于无去势抵抗生存与无转移生存高度相关,经验证后无去势抵抗生存可能作为局部治疗后生化复发并启动雄激素剥夺治疗男性的试验潜在中间终点。

研究设计与样本

  • 纳入根治性前列腺切除术后生化复发、PSA倍增时间<9个月且启动雄激素剥夺治疗时无转移的男性210例。
  • 主要目的为评估无去势抵抗生存与无转移生存的相关性,次要目的为评估转移时间与去势抵抗时间的相关性。
  • 使用Kendall's Tau检验主要和次要结局的相关性。

主要发现

  • 中位无转移生存为104个月(95%CI:83-114),中位无去势抵抗生存为100个月(95%CI:80-114)。
  • 根据Kaplan-Meier曲线,无转移生存与无去势抵抗生存差异最大处约在70%无生存率,无转移生存到达该点时间为61.2个月,无去势抵抗生存为49.6个月。
  • 无去势抵抗生存与无转移生存的Kendall's Tau为0.867(95%CI:0.765-0.968)。
  • 去势抵抗时间与转移时间的Kendall's Tau为0.764(95%CI:0.644-0.884)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metastasis-free survival (MFS) is a surrogate for overall survival (OS) in men with non-metastatic castration-resistant prostate cancer (CRPC), but this endpoint may take years to develop in men with non-metastatic castrate-sensitive disease. The study objective was to examine whether progression to CRPC is a potential intermediate endpoint for developing metastatic disease in patients with biochemical recurrence (BCR) after radical prostatectomy (RP). MATERIALS AND METHODS: Men with BCR following RP who had PSA doubling times (PSADT) < 9 months and no metastasis at the time of initiating androgen deprivation therapy (ADT) (n = 210) were included. The primary objective was to assess the correlation between CRPC-free survival (CRPC-FS) and MFS, and the secondary objective was to assess the correlation between time to metastasis and time to CRPC. Kendall's Tau was used to test the correlation for the primary and secondary outcomes. RESULTS: The median MFS was 104 months (95% CI: 83-114) and median CRPC-FS was 100 months (95% CI: 80-114). Based on the Kaplan-Meier curve, the greatest difference in time to MFS and CRPC-FS was around 70% free survival, which was reached at 61.2 months for MFS and 49.6 months for CRPC-FS. Kendall's Tau for the correlation between CRPC-FS and MFS and between time to CRPC and time to metastasis was 0.867 (95% CI: 0.765-0.968) and 0.764 (95% CI: 0.644-0.884), respectively. CONCLUSIONS: Given the high correlation between CRPC-FS and MFS, after validation, CRPC-FS may serve as a potential intermediate endpoint in trials for men with BCR initiating ADT following local therapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Klaassen Z, Howard L, Wallis CJD, et al. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)? Prostate Cancer Prostatic Dis. 2022. PMID: 36050455. doi:10.1038/s41391-022-00585-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。